Wussten Sie dass - Quellen

Quellenangaben: Wussten Sie, dass ...

- Saviez-vous que ...
- Lo sapevate, che ...

Argument 1:

- Innovation Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. U.S. Department of Health and Human Services. Food and Drug Administration (FDA), 2004, S.8
- Crawford, Lester M: Speech before PhRMA Annual Meeting. FDA (U.S. Food and Drug Administration), 2004
- FDA Drug Review: Postapproval Risks 1975-1985. U.S. General Accounting Office, Washington D.C.
- Lindl, T., Weichenmeier, I., Laban, D., Gruber F.P. und Manfred Völkel (2001); Altex 18, 171 - 178
- Hartung  T. Toxicology for the twenty-first century. Nature. 2009 Jul 9;460(7252):208-12

Argument 2:

- Bundesamt für Veterinärwesen BVET (http://www.tv-statistik.bvet.admin.ch/index.php)
- Taylor K., Gordon N., Langley G., Higgins W. (2008) Estimates for Worldwide Laboratory Animal Use in 2005. Alternatives to Laboratory Animals (ATLA), 36(3):327-342

Argument 3:

- Bundesamt für Veterinärwesen BVET (http://www.tv-statistik.bvet.admin.ch/index.php)
- Tierversuchsstatistik des Bundesamtes für Veterinärwesen (BveT) Schweiz 1984
- http://www.20min.ch/news/story/27315109
- Heinrich UR et al.: Endothelial nitric ocide synthase upregulation in the guinea pig organ o Corti after acute noise trauma. Brain Research, 2005, 1074: 85-96
- U. Trotzke et al.: The influence oft fasting on blood and plasma composition of herring gulls (Larus argentatus). Physiological and Biochemical Zoology 1999: 72(4), 426-437
-http://www.bvet.admin.ch/themen/tierschutz/00777/index.html?lang=de&download=NHzLpZeg7t,
lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDe4R4e2ym162epYbg2c_JjKbNoKSn6A—
Seite 27

Argument 4:

- Lazarou, J.; Pomeranz, B. H. und Corey, P. N.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279(15), S.1200-1205
-  Bailey, J; Knight, A und Balcombe, J: The future of teratology research is in vitro. Biogenic Amines, 2005, 19(2), S.97-145
- Topol, E. J.: Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med, 2004, 351(17), S.1707-1709
- DOLL, R. und HILL, A. B.: The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J, 1954, 1(4877), S.1451-1455
- Lindl, T., Weichenmeier, I., Laban, D., Gruber F.P. und Manfred Völkel (2001); Altex 18, 171 - 178
- Hartung  T. Toxicology for the twenty-first century. Nature. 2009 Jul 9;460(7252):208-12
 

Argument 5:

- http://www.wdr.de/tv/servicezeit/gesundheit/sendungsbeitraege/2008/1222/03_entstehung_von_medikamenten.jsp
- http://sciencev1.orf.at/torgersen/30742.html
- ZDF, Frontal 21 vom 9.12.2008, Dokumentation: Das Pharma-Kartell
- Gesundheitswesen Schweiz 2007 – 2009, Huber Verlag, Santésuisse und Nationale
Gesundheitspolitik Schweiz
- http://www.aerzteblatt.de/v4/archiv/artikel.asp?id=33824
- http://www.who.int/medicines/en/
- The pharmaceutical industry in figures
- http://sciencev1.orf.at/torgersen/30742.html

Argument 6:

HIV-/AIDS-Forschung:
- DeVita Jr., VT; Hellman, S und Rosenberg, SA: AIDS Etiology, Diagnosis, Treatment and Prevention. JB Lippincott, Philadelphia, 1992
- Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W. und Broder, S.: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A, 1985, 82(20), S.7096-7100
- Soudeyns, H.; Yao, X. I.; Gao, Q.; Belleau, B.; Kraus, J. L.; Nguyen-Ba, N.; Spira, B. und Wainberg, M. A.: Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother, 1991, 35(7), S.1386-1390
- Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A. und et, a. l..: Rational design of peptide-based HIV proteinase inhibitors. Science, 1990, 248(4953), S.358-361
- Hoffmann, Christian; Rockstroh, Jürgen K und Kamps, Bernd Sebastian: HIV.NET 2008. Steinhäuser Verlag, Wuppertal, 2008, S.104-108
- Gardner, MB und Luciw, PA: Animal Models of AIDS. FASEB Journal, 1989, 3, S.2593-2606
- O'Neil, S. P.; Novembre, F. J.; Hill, A. B.; Suwyn, C.; Hart, C. E.; Evans-Strickfaden, T.; Anderson, D. C.; deRosayro, J.; Herndon, J. G.; Saucier, M. und McClure, H. M.: Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis, 2000, 182(4), S.1051-1062
- Gauduin, M. C.; Parren, P. W.; Weir, R.; Barbas, C. F.; Burton, D. R. und Koup, R. A.: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med, 1997, 3(12), S.1389-1393
- Diseases, National InstituteofAllergyandInfectious: Clinical Trials of HIV Vaccines. URL: http://niaid.nih.gov/factsheets/clinrsch.htm, National Institutes of Health. U.S. Department of Health and Human Services, Abruf: 25.09.2008

Medizinische Errungenschaften ohne Tierversuche:
- Beeson, P. B.: The growth of knowledge about a disease: hepatitis. Am J Med, 1979, 67(3), S.366-370
- Good, R. A.: Presidential address to the American Association of Immunologists, delivered in Anaheim, California, April 13, 1976. Runestones in immunology: inscriptions to journeys of discovery and analysis. J Immunol, 1976, 117(5 Pt 1), S.1413-1428
- Good, R. A.: Keystones. Journal of Clinical Investigation, 1968, 47, S.1466-1471
- Heimlich, H. J. und Patrick, E. A.: The Heimlich maneuver. Best technique for saving any choking victim's life. Postgrad Med, 1990, 87(6), S.38-48, 53
- Sitaram, N und Gershon, S: Animal models to clinical testing – promises and pitfalls. In: Hrsg. unbekannt: Progress in Neuropsychopharmacology, Biology and Psychiatry. 1983, S.227-228
- Davis, JM: Antipsychotic drugs. In: Kaplan, HI et al. : Comprehensive Textbook of Psychiatry. William and Wilkins, Baltimore, 1985
- DOYLE, J. T.; DAWBER, T. R.; KANNEL, W. B.; KINCH, S. H. und KAHN, H. A.: THE RELATIONSHIP OF CIGARETTE SMOKING TO CORONARY HEART DISEASE; THE SECOND REPORT OF THE COMBINED EXPERIENCE OF THE ALBANY, NY. AND FRAMINGHAM, MASS. STUDIES. JAMA, 1964, 190, S.886-890
- KANNEL, W. B.; DAWBER, T. R.; THOMAS HE, J. r. und MCNAMARA, P. M.: COMPARISON OF SERUM LIPIDS IN THE PREDICTION OF CORONARY HEART DISEASE. FRAMINGHAM STUDY INDICATES THAT CHOLESTEROL LEVEL AND BLOOD PRESSURE ARE MAJOR FACTORS IN CORONARY HEART DISEASE; EFFECT OF OBESITY AND CIGARETTE SMOKING ALSO NOTED. R I Med J, 1965, 48, S.243-250
- Lewis, T: Clinical Science: for treating atrial fibrillation. Shaw and Sons Ltd., 1934
- Sneader, W: Drug Discovery: the Evolution of Modern Medicine. For treating heart failure. Wiley, 1985
- Bellet, S: Clinical Disorders of the Heart Beat. Lea and Febiger, 1971
- Vaughan Williams, EM: Antiarrhythmic Action and the Puzzle of Perhexiline. Academic Press, 1980
- Snell, ES: Pharmacy International, 1986,(Feb), S.33-37
- PEARSON, O. H.; ELIEL, L. P. und et, a. l..: Adrenocorticotropic hormone- and cortisone-induced regression of lymphoid tumors in man; a preliminary report. Cancer, 1949, 2(6), S.943-945
- Boesen, E: Cytotoxic Drugs in the Treatment of Cancer. Edward Arnold, London, 1969, S.24
- Coley, WB: A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate, 1893, 8, S.278-286
- Caldwell, A: Origins of Psychopharmacology: From CPZ to LSD. Charles C Thomas, Springfield, 1970
- Lehmann, HE und Kline, NS: Clinical discoveries with antidepressant drugs. In: Parnham, MJ et al. : Discoveries in Pharmacology. Elsevier, New York, 1983, S.209-221
- Sulser, F und Mishra, R: The discovery of tricyclic antidepressants and their mode of action. In: Parnham, MJ et al. : Discoveries in Pharmacology. Elsevier, New York, 1983, S.233-247
- Silverman, W. A.: The schizophrenic career of a «monster drug». Pediatrics, 2002, 110(2 Pt 1), S.404-406
- GOOD, R. A.; VARCO, R. L.; AUST, J. B. und ZAK, S. J.: Transplantation studies in patients with agammaglobulinemia. Ann N Y Acad Sci, 1957, 64(5), S.882-924; discussion, 924
- Palca, J.: Insights from broken brains. Science, 1990, 248(4957), S.812-814

Argument 7:

- H. Bekemeier: Salicylamid- und Salicylsäure-Vergiftung bei der Katze im Vergleich mit anderen Tieren. I., in: Arzneimittelforschung, 1955, 5, S. 572–575; PMID 13276287 (http://www.ncbi.nlm.nih.gov/pubmed/13276287?dopt=Abstract)
- Wolfgang Löscher et al: Grundlagen der Pharmakotherapie bei Haus- und Nutztieren, 2. Auflage, Parey 1994, S. 104 und 210
- R.Sharpe, The Cruel Deception, Thorsons, 1988 (und ff. Zitate)
 - http://www.aerzte-gegen-tierversuche.de/infos/humanmedizin/102-wissenschaftliche-argumente-gegen-tierversuche

Argument 8:

- http://www.snf.ch/SiteCollectionDocuments/por_fac_rg_jb07_d.pdf
- http://www.forschung3r.ch/de/information/jb08.html
- http://www.lscv.ch/de/pages/tierversuche/bize/snf.html
- http://www.lscv.ch/de/pages/news/fondation3r_de.html

Argument 9:

- ZDF, Frontal 21 vom 9.12.2008, Dokumentation: Das Pharma-Kartell
- http://www.admin.ch/ch/d/gg/pc/documents/1704/Bericht2.pdf (und Anhänge)
- http://www.admin.ch/ch/d/gg/pc/documents/1704/Ergebnisbericht2.pdf
-http://www.bvet.admin.ch/themen/tierschutz/00777/index.html?lang=de&download=NHzLpZeg7t,
lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDe4R4e2ym162epYbg2c_JjKbNoKSn6A—
Seite 27
- Tierschutzgesetz: http://www.admin.ch/ch/d/sr/455/
- Tierschutzverordnung: http://www.admin.ch/ch/d/sr/455_1/index.html
- Gesundheitswesen Schweiz 2007 – 2009, Huber Verlag, Ermöglicht durch: Santésuisse und Nationale Gesundheitspolitik Schweiz, Seite 181
http://www.snf.ch/SiteCollectionDocuments/Dossiers/dos_primatenversuche_lis_07_d.pdf